miscsubjectsAI governance
Evidence review

PT-141 and GLP-1 Agonists: Evidence-Graded Look at Combination Use

· · 4 min read
bundle · json · system map · manifest

Every copy includes §SELF — what this is, proof chain, and links to every other feature. No context required.

§SELF — this page explains the system
## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `human_page` — **Human article page**
Rendered article with claims, sources, copy widgets, ask prompts.
- **article slug:** `pt-141-glp-1`
- **contains:** rendered article, copy widgets, claims, sources, ask prompts
- **how to use:** Use Copy for LLM or Copy system map — both paste without context.
- **read:** https://miscsubjects.com/a/pt-141-glp-1

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/pt-141-glp-1/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/pt-141-glp-1/bundle?format=markdown
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/pt-141-glp-1/prompts
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/pt-141-glp-1/topology

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

*Not medical advice. Tier-honest. Cite claim/source ids.*

What's breaking down

The body is always doing two things at once: breaking down (degeneration) and building back (regeneration). A condition persists when breakdown outruns repair. Most drugs used for symptoms suppress a signal (pain, acid, anxiety, inflammation) without fixing the tissue that caused the signal. Peptides in this ledger are studied for repair pathways: new blood vessels, repair-cell migration, nerve regrowth, gut lining, neural connections. This article maps one compound through that frame — what it is, how it is proposed to work, what evidence exists, and what people report.

Why PT-141 might help you

  1. Therefore for you: If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.

Why GLP-1 agonists (class) matters for you

  1. Drug: GLP-1 agonists (class)
  2. What it does: Metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss.
  3. Therefore for you: state whether this drug reduces load, suppresses a signal, or supports metabolism — and whether that helps or trades off repair for your condition.

How these fit together

Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.

  • PT-141 → sexual / CNS arousal

What the evidence actually shows

This is a count of what is in this ledger — not a claim about all research worldwide.

  • Scientific sources catalogued (PubMed, trials, reviews): 3
  • Claims tagged human evidence: 4
  • Claims tagged preclinical (animal/lab): 0
  • Claims tagged anecdotal: 1
  • Reddit posts catalogued: 1
  • X posts catalogued: 0
  • Other anecdote sources (YouTube, Instagram, etc.): 0
  • Total sources in chain: 5

Quantified confidence (this ledger): 0.57 / 1.00 — moderate — human claims present in ledger

Formula: human claims×0.12 + preclinical×0.04 + anecdote×0.015 + studies (capped). This is not clinical certainty — it measures how much graded evidence is catalogued here.

What scientists say

Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder (source s1)

Phase 3 RECONNECT trials results.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

Anorgasmia following initiation of GLP-1 agonist (source s14)

Case of GLP-1 linked anorgasmia.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

Male sexual dysfunction associated with GLP-1 receptor agonists: a cross-sectional analysis of FAERS data (source s30)

FAERS disproportionality analysis.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

What people say on Reddit

Are GLP-1 Medications Affecting Your Libido? — Reddit, r/glp1 (source s33)

User reports of libido change on GLP-1.

---

Not medical advice. Counts and quotes are from this article's hash-chained ledger. Anecdote = real reports, not proof. Animal studies ≠ human proof.

Explore this article's relationships

GLP-1 agonists · drug map

Connected articles

Where this sits in the evidence graph. Open the full interactive map for the whole neighborhood.

Full map →
RelatedPT-141: Brain-Level Arousal · 17 humanPT-141 (Bremelanotide) and Sexual Dysfunction in the Context of Blood… · 8 humanPT-141 for Chemotherapy Side Effects: Evidence on Sexual Arousal Pathw… · 3 humanPT-141 for Diabetic Neuropathy: Evidence-Graded Review · 3 human
Evidence · 5 sources · swipe →chain cc533e66f90b · verify chain · provenance
1 / 5
Evidence ledger 5 · tier-ranked · API
human
Two phase 3 RECONNECT trials showed bremelanotide improved sexual desire and reduced distress in premenopausal women with HSDD versus placebo (human).
sources: s1
human
BMT-801 phase 2 trial met primary endpoint: low-dose bremelanotide plus tirzepatide produced additive/synergistic weight loss and prevented post-tirzepatide regain without added safety signals (human, 2025).
sources: s9
human
Case reports link GLP-1 initiation to anorgasmia that resolved on tirzepatide switch (human).
sources: s14
humanlow confidence
FAERS analysis found weak association between GLP-1 agonists and reported male sexual dysfunction (human).
sources: s30
anecdotallow confidence
Reddit users on GLP-1 report libido reduction and discuss PT-141 as a possible counter for the arousal layer (anecdotal).
sources: s33
Model review1 contributions · 1 modelExpand the recursive review layer
1 / 1
grok/grok-4.3writer
redraft2026-06-30 01:17
PT-141 and GLP-1 Agonists: Evidence-Graded Look at Combination Use · 5 claims · 5 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: Write a data-first, evidence-graded article: PT 141 for Glp 1
Slug: pt-141-glp-1
Audience: readers researching peptide evidence for this specific condition or drug cross.
Rules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.

ENRICHMENT BRIEF (binding section logic — one ## per compound):
{"voice":"enrichment","article_shape":"single_focus","condition":null,"condition_key":null,"primary_peptide":null,"peptides_in_scope":[{"id":"pt-141","name":"PT-141"}],"drugs_in_scope":["glp1-agonists"],"weight_sensitive":false,"stimulant_context":false,"breaking_down":{"section_title":"What's breaking down","degenerative_why":[],"degener
it output
{
  "slug": "pt-141-glp-1",
  "title": "PT-141 and GLP-1 Agonists: Evidence-Graded Look at Combination Use",
  "body": "## What's breaking down\n\nNo single disease profile is tied to the slug, but the cross points to two overlapping layers: metabolic regulation (appetite, weight, energy balance) and central nervous system arousal pathways (sexual desire via melanocortin receptors). GLP-1 agonists primarily act on metabolic and gut signals. PT-141 targets melanocortin-4 receptors (MC4R) in the brain. When these layers interact, the question becomes whether one pathway supports or trades off against the other.\n\n## Why PT-141 might help you\n\nPT-141 (bremelanotide) is discussed for the sexual / CNS arousal layer. If that layer is part of your problem while using GLP-1 agonists, the compound is examined because it engages central melanocortin pathways that influence desire and arousal rather than masking symptoms. Step one: MC4R activation occurs in brain regions tied to reward and sexual response. Step two: this occurs independently of blood-flow mechanisms used by PDE5 inhibitors. Step three: therefore, if GLP-1 use coincides with reduced desire reports, PT-141 is studied for its distinct central action on that specific layer.\n\n## Why GLP-1 agonists (class) matters for you\n\nGLP-1 agonists support metabolism through appetite reduction and improved glycemic control. This ca
0766d7370bf77876
Machine verification: /api/articles/pt-141-glp-1/contributions

Latest from the journal

Most recent pieces, site-wide

All articles →
The Disc Stackposted 2026-07-24the-disc-stackHerniated Discposted 2026-07-24herniated-discDegenerative Disc Diseaseposted 2026-07-24degenerative-disc-diseaseBPC-157 vs NSAIDs: Repair or Suppress?posted 2026-07-24bpc-157-vs-nsaidsAgentKit: a post-mortem in advanceposted 2026-07-24what-agentkit-was

Related articles

GLP-1 agonists · drug map

Open evidence map →
PT-141: Brain-Level Arousalpt-141PT-141 and Benzodiazepine Withdrawal: A Data-First Evidence Reviewpt-141-benzo-withdrawalPT-141 and Benzodiazepines: Evidence Review on CNS Arousal Layerspt-141-benzodiazepinesPT-141 (Bremelanotide) and Sexual Dysfunction in the Context of Blood…pt-141-blood-pressure-medsPT-141 for Statin-Associated Cognitive Effects: Evidence Reviewpt-141-brain-fogPT-141 for Carpal Tunnel Syndrome: A Data-First Evidence Reviewpt-141-carpal-tunnel
Ask this article · 8 suggested prompts
topology · JSON · question graph

Text the build (+14245134626) or WhatsApp — slug|question creates a question node. Paste evidence with ingest slug|q:NODE_ID|your paste.

What does the ledger say about this (human tier): "Two phase 3 RECONNECT trials showed bremelanotide improved sexual desire and reduced distress in premenopausal women with HSDD versus placeb…"?
ask pt-141-glp-1 claim c1 · paste includes §SELF
What does the ledger say about this (human tier): "BMT-801 phase 2 trial met primary endpoint: low-dose bremelanotide plus tirzepatide produced additive/synergistic weight loss and prevented …"?
ask pt-141-glp-1 claim c2 · paste includes §SELF
What does the ledger say about this (human tier): "Case reports link GLP-1 initiation to anorgasmia that resolved on tirzepatide switch (human)."?
ask pt-141-glp-1 claim c3 · paste includes §SELF
What does the ledger say about this (human tier): "FAERS analysis found weak association between GLP-1 agonists and reported male sexual dysfunction (human)."?
ask pt-141-glp-1 claim c4 · paste includes §SELF
What does the ledger say about this (anecdotal tier): "Reddit users on GLP-1 report libido reduction and discuss PT-141 as a possible counter for the arousal layer (anecdotal)."?
ask pt-141-glp-1 claim c5 · paste includes §SELF
Summarize this reddit report and how it should weigh: "User reports of libido change on GLP-1."
ask pt-141-glp-1 source s33 · paste includes §SELF
For my medical situation, what can you answer from your catalogue about PT-141 and GLP-1 Agonists: Evidence-Graded Look at Combination Use — and what would you need me to tell you first?
ask pt-141-glp-1 condition gaps · paste includes §SELF
What good and bad outcomes are documented for PT-141 and GLP-1 Agonists: Evidence-Graded Look at Combination Use (studies vs anecdotes)?
ask pt-141-glp-1 good bad experiences · paste includes §SELF
Add your experience or question
Think this article is wrong?
Dispute this article in Claim Audit →